Showing 1 - 10 of 38,885
This paper describes the key principles of why an assessment of uncertainty and its consequences are critical for the types of decisions that a body such as the UK National Institute for Health and Clinical Excellence (NICE) has to make. In doing so, it poses the question of whether formal...
Persistent link: https://www.econbiz.de/10005243089
Economists engaged in comparative effectiveness research (CER) commonly adopt particular value judgements that underpin many of their methods. Two of these are the idea of a 'societal perspective' and that the foundation of values in measures of health outcome is individual preferences. This...
Persistent link: https://www.econbiz.de/10008519888
Persistent link: https://www.econbiz.de/10008519896
The application of cost-effectiveness analysis in healthcare has become commonplace in the US, but the validity of this approach is in jeopardy unless the proverbial $US50 000 per QALY benchmark for determining value for money is updated for the 21st century. While the initial aim of this...
Persistent link: https://www.econbiz.de/10008521841
Since 1999, the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Programme has been charged with producing guidance for the NHS in England and Wales on the appropriate use of new and existing healthcare programmes. Guidance is based on an assessment of a number...
Persistent link: https://www.econbiz.de/10005449300
This article reviews the general issues in valuing health states for use in cost-effectiveness analysis and the specific issues considered by the National Institute for Health and Clinical Excellence (NICE) in its recent review of the methods of technology appraisal. The general issues are how...
Persistent link: https://www.econbiz.de/10005449318
Discrete choice experiments (DCEs) are regularly used in health economics to elicit preferences for healthcare products and programmes. There is growing recognition that DCEs can provide more than information on preferences and, in particular, they have the potential to contribute more directly...
Persistent link: https://www.econbiz.de/10005404768
The National Institute for Health and Clinical Excellence (NICE) has been using a cost-effectiveness threshold range between Lstg 20_000 and Lstg 30_000 for over 7 years. What the cost-effectiveness threshold represents, what the appropriate level is for NICE to use, and what the other factors...
Persistent link: https://www.econbiz.de/10005404787
DOI: 10.2165/0019053-200826110-00002
Persistent link: https://www.econbiz.de/10005404814
DOI: 10.2165/0019053-200826090-00003
Persistent link: https://www.econbiz.de/10005404908